斯派尔治疗
SYRE
79.90
-0.20
-0.25%
斯派尔治疗
US · SYRE
#1646 按市值排名
上市于 1970
79.90
-0.20
-0.25%
实时 - 追踪5344个代码 - 心跳于295秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了8家。
- 机构持股总比例上升了0.9个百分点。
机构持股
- 机构持股比例
- 110.86% +0.91pp
- 机构数量
- 333 +8
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund71.78%
Hedge Fund22.21%
VC/PE Fund11.75%
Individual/Insider5.70%
Public Company4.02%
Private Company0.56%
Government Pension Fund0.31%
Insurance Company0.20%
主要股东 截至 2026-06-30
FMR
14.77% · 13.03M 股
BlackRock
7.38% · 6.51M 股
Paradigm Biocapital Advisors LP
5.06% · 4.46M 股
Perceptive Advisors LLC
4.90% · 4.32M 股
RTW Investments, LP
4.82% · 4.25M 股
Vanguard Capital Management, LLC
4.54% · 4.00M 股
Peter Deutsch
4.03% · 3.55M 股
Capital Research
3.71% · 3.27M 股
State Street Global Advisors
3.47% · 3.06M 股
VR Management, LLC
3.39% · 2.99M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 13次买入 · 37次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Cameron Turtle | COO & Principal Executive Officer | 0.61% |
| Tomas Kiselak | Director | 0.46% |
| Peter Harwin | Director | 0.46% |
| Michael Henderson | Director | 0.08% |
| Scott Burrows | Chief Financial Officer | 0.05% |
| Jeffrey Albers | Director | 0.01% |
| Heidy King-Jones | Chief Legal Officer | 0.00% |
| Mark McKenna | Independent Director | -- |
| Laurie Stelzer | Director | -- |
| Fairmount Funds Management LLC | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Cameron Turtle | COO & Principal Executive Officer | Automatic Disposition | -15,000 | $89.14–93.91 |
| 2026-09-30 | Heidy King-Jones | Chief Legal Officer | Derivative Exercise and Sale | -28,933 | $14.50–93.46 |
| 2026-09-30 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -25,000 | $14.50–93.57 |
| 2026-09-29 | Scott Burrows | Chief Financial Officer | Intent to Sell (Form 144) | -17,500 | $89.89 |
| 2026-09-01 | Heidy King-Jones | Chief Legal Officer | Derivative Exercise and Sale | -28,399 | $14.50–90.00 |
| 2026-09-01 | Scott Burrows | Chief Financial Officer | Open Market Disposition | -18,232 | $89.35 |
| 2026-08-31 | Cameron Turtle | COO & Principal Executive Officer | Automatic Disposition | -15,000 | $86.36–89.07 |
| 2026-08-31 | Heidy King-Jones | Chief Legal Officer | Intent to Sell (Form 144) | -46,665 | $89.33 |
| 2026-08-31 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -7,500 | $14.50–89.04 |
| 2026-08-06 | Jeffrey Albers | Director | Automatic Disposition | -18,000 | $104.38–104.68 |
| 2026-08-06 | Jeffrey Albers | Director | Derivative Exercise and Sale | -5,000 | $10.39–104.47 |
| 2026-08-02 | Cameron Turtle | COO & Principal Executive Officer | Automatic Disposition | -15,000 | $93.97–97.46 |
| 2026-08-02 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -7,500 | $14.50–97.10 |
| 2026-06-30 | Cameron Turtle | COO & Principal Executive Officer | Automatic Disposition | -15,000 | $87.44–88.91 |
| 2026-06-30 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -7,500 | $14.50–88.37 |
| 2026-06-30 | Sheldon Sloan | Chief Medical Officer | Derivative Exercise and Sale | -8,334 | $27.46–88.34 |
| 2026-06-24 | Scott Burrows | Chief Financial Officer | Derivative Exercise and Sale | -15,000 | $14.50–87.14 |
| 2026-06-22 | Fairmount Funds Management LLC | -- | Private Disposition | -4,018,101 | $85.31 |
| 2026-06-22 | Fairmount Funds Management LLC | -- | Derivative Exercise and Sale | -666,680 | $85.31 |
| 2026-06-21 | Michael Henderson | Director | Automatic Disposition | -20,000 | $100.00 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
斯派尔治疗 讨论区 0 条评论